Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Ono Pharmaceutical Co Ltd | 67 |
| 2 | Fate Therapeutics Inc | 13 |
| 3 | Fuji Chemical Industries Co Ltd | 12 |
| 4 | Daiichi Sankyo Co Ltd | 10 |
| 5 | Sanofi SA | 9 |
| 6 | Chinese Academy of Sciences | 8 |
| 7 | Asahi Kasei Corp | 7 |
| 8 | SBI Holdings Inc | 6 |
| 9 | Suzuken Co Ltd | 6 |
| 10 | Commissariat à l'Énergie Atomique et Aux Énergies Alternatives | 5 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 184 |
| 2 | A61K | Medicinal preparations | 175 |
| 3 | C07D | Heterocyclic compounds | 109 |
| 4 | G01N | Investigating / analysing materials | 52 |
| 5 | C12N | Microorganisms, enzymes | 44 |
| 6 | Y02A | Climate change adaptation | 37 |
| 7 | C12P | Fermentation, enzyme processes | 17 |
| 8 | Y10T | Cross-reference (technical subjects) | 17 |
| 9 | Y10S | Cross-reference (legacy) | 16 |
| 10 | C07H | Sugars and derivatives | 15 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Process for preparing protoporphyrin disodium salt | 2003 | 3 | |
| PRODUCTION OF PROTOPORPHYRIN DISODIUM SALT | 1988 | Sanofi SA | 2 |
| A kind of preparation method of protoporphyrin disodium | 2018 | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 97 |
| 2017 | 77 |
| 2018 | 83 |
| 2019 | 94 |
| 2020 | 65 |
| 2021 | 60 |
| 2022 | 21 |
| 2023 | 19 |
| 2024 | 77 |
| 2025 | 38 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Johan Moan | Norwegian Cancer Society | 38 |
| 2 | Tayyaba Hasan | Massachusetts General Hospital | 24 |
| 3 | Hans Christian Wulf | Bispebjerg Hospital | 19 |
| 4 | Vladimir Iani | Norwegian Cancer Society | 18 |
| 5 | Petras Juzenas | Norwegian Cancer Society | 16 |
| 6 | Norbert Lange | École Polytechnique Fédérale de Lausanne | 15 |
| 7 | Asta Juzeniene | Norwegian Cancer Society | 14 |
| 8 | Qian Peng | Oslo University Hospital | 14 |
| 9 | Brian W. Pogue | Dartmouth College | 14 |
| 10 | Georges Wagnières | École Polytechnique Fédérale de Lausanne | 12 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Photodynamic therapy with endogenous protoporphyrin | 1990 | 1531 | Photodynamic Therapy Research Studies |
| The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria | 2002 | 822 | Drug Transport and Resistance Mechanisms |
| 5‐Aminolevulinic Acid‐Based Photodynamic Therapy: Principles and Experimental Research | 1997 | 622 | Nanoplatforms for cancer theranostics |
| Chloroplast to nucleus communication triggered by accumulation of Mg-protoporphyrinIX | 2003 | 591 | Plant Molecular Biology Research |
| Graphene as a Substrate To Suppress Fluorescence in Resonance Raman Spectroscopy | 2009 | 528 | Gold and Silver Nanoparticles Synthesis and Applications |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Protoporphyrin disodium?
Which organizations hold the most patents related to Protoporphyrin disodium?
What are the dominant patent classifications for Protoporphyrin disodium?
Who are the most prolific authors publishing on Protoporphyrin disodium?
What is the research publication trend for Protoporphyrin disodium in recent years?